Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 1.00 |
| ▸ | CTSL | P07711 | 4/20 | 1.00 |
| ▸ | GHSR | Q92847 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21065454 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL26993704 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL29367405 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL30472916 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL25422114 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL25424145 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL30913016 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL29411985 | 1.00 | CTSV (1.00) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL2821600 | 0.98 | CTSV (0.97) | CTSVCTSLGHSRHSD17B10KDM4E | |
| SCHEMBL7835926 | 0.94 | CTSV (0.88) | CTSVCTSLGHSRHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230184759-A1 | IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2023-06-15 | — | — | US | claimed |
| EP-4126820-A1 | IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA | Consejo Superior De Investigaciones Científicas (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2021198064-A1 | IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2021-10-07 | — | — | WO | claimed |
| US-20190270909-A1 | CONTROLLED RELEASE OF WATER-SOLUBLE AGENTS | THE SECANT GROUP, LLC | 2019-09-05 | — | — | US | claimed |
| US-10329448-B2 | Method of making coated articles | THE SECANT GROUP, LLC (US) | 2019-06-25 | — | — | US | claimed |
| US-20160251540-A1 | METHOD OF MAKING COATED ARTICLES | THE SECANT GROUP, LLC | 2016-09-01 | — | — | US | claimed |
| US-20260138981-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS | THE TRUSTEES OF PRINCETON UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4702981-A1 | TARGETED ANTIBACTERIAL TREATMENT | Københavns Universitet (DK) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024077235-A9 | DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-118063452-A | Benzothiazole or benzoxazole derivative and preparation method and application thereof | 山东大学 | 2024-05-24 | — | — | CN | disclosed |
| EP-4365928-A2 | SPECTROMETRIC ANALYSIS OF MICROBES | Micromass UK Limited (GB) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024077235-A2 | DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-04-11 | — | — | WO | disclosed |
| CN-115477610-B | Preparation method of C-3 perfluoroalkyl 4-quinolinone compound | 河北农业大学 | 2024-03-15 | — | — | CN | disclosed |
| US-7371779-B2 | Synergistic compositions of N-acylhomoserine lactones and 4-quinolones | THE SECRETARY OF STATE FOR DEFENSE SCIENCE AND TECHNOLOGY (GB) | 2008-05-13 | — | — | US | disclosed |
| EP-1349550-B1 | SUBSTITUTED-4-QUINOLONES FOR THE TREATMENT OF AUTOIMMUNE DISEASES | SECR DEFENCE (GB) | 2006-06-14 | — | — | EP | disclosed |
| EP-1404315-B1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | UNIV NOTTINGHAM (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-20040198978-A1 | Synergistic compositions of n-acylhomoserine lactones and 4-quinolones | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2004-10-07 | — | — | US | disclosed |
| US-20040082579-A1 | Immunosuppressant | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1404315-A1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004017-A1 | SYNERGISTIC COMPOSITIONS OF N-ACYLHOMOSERINE LACTONES AND 4-QUINOLONES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230184759-A1 | IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA | QSOX1, QARS1, CD47 | CTSV 4321/4885CTSL 3138/4885GHSR 1122/4885 |
| US-10329448-B2 | Method of making coated articles | SGMS2, SGMS1, RHOA | CTSV 4301/4885CTSL 3904/4885GHSR 2351/4885 |
| US-20260138981-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS | DHFR, CBR1, DHRS9 | CTSV 3677/4885CTSL 1324/4885GHSR 1425/4885 |
| US-20160251540-A1 | METHOD OF MAKING COATED ARTICLES | SGMS2, SGMS1, RHOA | CTSV 4301/4885CTSL 3904/4885GHSR 2351/4885 |
| US-20040082579-A1 | Immunosuppressant | CCR6, CCR1, CCR8 | CTSV 3955/4885CTSL 4059/4885GHSR 737/4885 |
| US-20190270909-A1 | CONTROLLED RELEASE OF WATER-SOLUBLE AGENTS | ADH1A, ADH1C, MLEC | CTSV 3794/4885CTSL 2176/4885GHSR 255/4885 |
| US-20040198978-A1 | Synergistic compositions of n-acylhomoserine lactones and 4-quinolones | CBR3, CBR1, CNR1 | CTSV 4696/4885CTSL 3582/4885GHSR 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.